Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Mei Yan Pang"'
Autor:
Jingshan Ho, Valerie Heong, Wei Peng Yong, Ross Soo, Cheng Ean Chee, Andrea Wong, Raghav Sundar, Yee Liang Thian, Anil Gopinathan, Mei Yan Pang, Priscillia Koe, Santhiay Nathan Jeraj, Phyu Pyar Soe, Mu Yar Soe, Tiffany Tang, Matthew C.H. Ng, David W.M. Tai, Tira J.Y. Tan, Hongmei Xu, Hua Chang, Yosef Landesman, Jatin Shah, Sharon Shacham, Soo Chin Lee, Daniel S.W. Tan, Boon Cher Goh, David S.P. Tan
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Purpose: This phase 1 study aims to evaluate the tolerability and the recommended phase 2 dose of selinexor in Asian patients with advanced or metastatic malignancies. Experimental Design: A total of 105 patients with advanced malignancies were enrol
Externí odkaz:
https://doaj.org/article/c79a3aab5cd24242a6a55312f1cb0bbf
Publikováno v:
ICMLC
Intelligent vehicle monitoring system is collecting and processing the large amounts of information all the time. The paper applies data warehouse technique to intelligent vehicle monitoring system to store and manage the information. Based on the an
Autor:
Cheng Ean Chee, Wei Peng Yong, Sharon Friedlander, Raghav Sundar, Yee Liang Thian, Dilara McCauley, Priscillia Koe, Sharon Shacham, David Shao Peng Tan, Tami Rashal, Yosef Landesman, Boon Cher Goh, Ross A. Soo, Anil Gopinathan, Mei-Yan Pang, Soo-Chin Lee, Andrea Li Ann Wong, Jingshan Ho
Publikováno v:
Journal of Clinical Oncology. 33:2542-2542
2542 Background: SXR is an orally administered potent XPO1 inhibitor that forces nuclear retention and activation of multiple tumor suppressor proteins resulting in tumor cell death. SXR was evalua...
Autor:
Samuel Guan Wei Ow, Yoon Sim Yap, Soo-Chin Lee, Shaik Ahmad Buhari, Mikael Hartman, Chee Seng Tan, Yi Wan Lim, Angela Pang, Philip Iau, Jean Paul Thiery, Mei-Yan Pang, Anthony Tang, Raghav Sundar, Bee Luan Khoo, Jingshan Ho, Sing Huang Tan, Ching Wan Chan, Nan-Soon Wong, I Peng Thomas Soh, Andrea Li Ann Wong
Publikováno v:
Journal of Clinical Oncology. 32:619-619
619^ Background: The optimal neoadjuvant regimen in HER2+ breast cancer is undefined. We evaluated the efficacy and tolerability of weekly paclitaxel/carboplatin with lapatinib. Methods: HER2+ stage I-III breast cancer patients received 4 cycles of 3
Autor:
Ho, Jingshan, Heong, Valerie, Peng Yong, Wei, Soo, Ross, Ean Chee, Cheng, Wong, Andrea, Sundar, Raghav, Liang Thian, Yee, Gopinathan, Anil, Yan Pang, Mei, Koe, Priscillia, Nathan Jeraj, Santhiay, Pyar Soe, Phyu, Yar Soe, Mu, Tang, Tiffany, Ng, Matthew C.H., Tai, David W.M., Tan, Tira J.Y., Xu, Hongmei, Chang, Hua
Publikováno v:
Therapeutic Advances in Medical Oncology; 4/11/2022, p1-18, 18p
Autor:
Ho, Jingshan, Heong, Valerie, Peng Yong, Wei, Soo, Ross, Ean Chee, Cheng, Wong, Andrea, Sundar, Raghav, Liang Thian, Yee, Gopinathan, Anil, Yan Pang, Mei, Koe, Priscillia, Nathan Jeraj, Santhiay, Pyar Soe, Phyu, Yar Soe, Mu, Tang, Tiffany, Ng, Matthew C.H., Tai, David W.M., Tan, Tira J.Y., Xu, Hongmei, Chang, Hua, Landesman, Yosef, Shah, Jatin, Shacham, Sharon, Chin Lee, Soo, Tan, Daniel S.W., Cher Goh, Boon, Tan, David S.P.
Supplemental material, sj-docx-2-tam-10.1177_17588359221087555 for A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in As
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b4a66939434b4d516d3692c31054ba1
Autor:
Ho, Jingshan, Heong, Valerie, Peng Yong, Wei, Soo, Ross, Ean Chee, Cheng, Wong, Andrea, Sundar, Raghav, Liang Thian, Yee, Gopinathan, Anil, Yan Pang, Mei, Koe, Priscillia, Nathan Jeraj, Santhiay, Pyar Soe, Phyu, Yar Soe, Mu, Tang, Tiffany, Ng, Matthew C.H., Tai, David W.M., Tan, Tira J.Y., Xu, Hongmei, Chang, Hua, Landesman, Yosef, Shah, Jatin, Shacham, Sharon, Chin Lee, Soo, Tan, Daniel S.W., Cher Goh, Boon, Tan, David S.P.
Supplemental material, sj-docx-1-tam-10.1177_17588359221087555 for A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in As
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40a3a1911d9e96f7295bb2558eda7c5e